Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 17, 2026

Gold Terra Announces Assay Results of 8.2 g/t Gold over 20.35 Metres in the Yellorex Area, Con Mine Option Property, Yellowknife, NWT

View original at finance.yahoo.com
Gold Terra Announces Assay Results of 8.2 g/t Gold over 20.35 Metres in the Yellorex Area, Con Mine Option Property, Yellowknife, NWT VANCOUVER, BC / ACCESS Newswire / March 17, 2026 / Gold Terra Resource Corp…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With Gold Terra's last MRE completed in 2022 based on a US$1750 gold price, our winter drill program of 10,000 metres in the Yellorex area will be looking to confirm and expand Gold Terra's estimate of the near surface resource from surface to 500 metres below surface

    60% confidence

  • Approximately 14 million ounces of gold has been produced from the Campbell Shear

    60% confidence

  • First batch of drill results confirm the potential continuity of the zone, as Gold Terra requires additional holes to seek more ounces in the indicated category

    60% confidence

  • Con Mine produced 6.1 million ounces between the Con, Rycon, and Campbell shear structures from 1938 to 2003

    60% confidence

  • The Campbell Shear structure is our highest priority target as the Con Mine produced historically more than 5 million ounces of high-grade gold (16 g/t Au)

    60% confidence

  • Yellorex Main Zone holes drilled on 30-50 metre spacing in 2021-2022 account for more than 65% of the 2022 MRE calculated by Gold Terra

    60% confidence

  • All Yellorex drill holes intersected the Campbell Shear, characterized by quartz-ankerite and smoky quartz veining with strong sericite-dominated alteration

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com